G1 Therapeutics

The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week
Yahoo/Benzinga
Mon, 02/15/21 - 10:37 am
earnings
FDA
G1 Therapeutics
trilaciclib
Zoetis
EXACT Sciences
Blueprint Medicines
Ironwood Pharmaceuticals
With a potential FDA approval looming, G1 Therapeutics taps ex-GSK US president Jack Bailey as new CEO
Endpoints
Thu, 10/1/20 - 11:04 pm
G1 Therapeutics
GSK
John Bailey
Mark Velleca
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
Sun, 09/22/19 - 11:10 pm
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
These 3 Biotech Stocks Skyrocketed Last Week
Motley Fool
Mon, 06/24/19 - 09:42 am
Array Biopharma
Pfizer
M&A
G1 Therapeutics
trilaciclib
Cel-Sci
Ex-GSK CEO Andrew Witty goes biotech, taking a board seat at G1
Endpoints
Thu, 07/13/17 - 09:45 am
GSK
Andrew Witty
biotech
Pharma CEOs
G1 Therapeutics
G1 Therapeutics joins a growing biotech winners circle with $105M IPO
Endpoints
Wed, 05/17/17 - 09:47 am
G1 Therapeutics
IPOs
Hey Pfizer, Novartis and Eli Lilly. G1 Therapeutics says it can beat all of you in its $115M IPO
Endpoints
Tue, 04/18/17 - 08:58 pm
G1 Therapeutics
IPOs
Pfizer
Novartis
Eli Lilly
cancer
R&D
G1 Therapeutics banks $33M to cut in on a blockbuster oncology race
Fierce Biotech
Thu, 02/5/15 - 05:00 pm
G1 Therapeutics
oncology
G1T28